Merck KGaA's Schistosomiasis Drug Shows Positive Results in Phase-3 Children Trial
16 Novembro 2021 - 5:51AM
Dow Jones News
By Cecilia Butini
Merck KGaA said Tuesday that a phase-3 trial to assess the
efficacy of a drug to cure tropical disease schistosomiasis in
children has met its primary endpoint of clinical cure in children
aged three months to six years.
The German pharmaceuticals-and-chemicals company said the drug,
which is named arpraziquantel, showed cure rates close to or above
90% in children infected with two different parasites that cause
the disease.
The trial demonstrated safety, tolerability and palatability of
the drug--which is administered as an orally dispersible
tablet--among pre-school children, the company said.
Merck intends to apply for a scientific opinion at the European
Medicines Agency under a procedure for high-priority medicines
intended for markets outside the European Union, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 16, 2021 03:36 ET (08:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
